Nutzungshinweis

Dieses Material ist freigegeben:

Image: xur Präsentation durch Novartis vor Fachkreisangehörigen/ Partner im Gesundheitswesen¹

und zwar

ohne Geheimhaltungsvereinbarung

und wurde

lokal erstellt/abgeändert

 zur Abgabe an Fachkreisangehörige/ Partner im Gesundheitswesen durch²: Mitarbeiter aus der Medizin

mit Geheimhaltungsvereinbarung

- global erstellt, ohne inhaltliche Änderungen. Durch Projektleiter vor Nutzung auf Übereinstimmung mit lokalen Vorgaben geprüft
- Dieses Material ist nicht für werbliche Zwecke bestimmt.
- Novartis übernimmt keine Verantwortung für Änderungen des Inhalts durch Externe
- Dieses Material entspricht den Prinzipien und Standards der globalen Novartis P3-Richtlinie
- Stand 12/2020

1 Fachtweisangehörlige sind Ärzte, Zahnärzte, Apatheker und Personen, die mit diesen Arzneinitteln erlaubterweise Handel treiben (HWG). Partner im Gesundheitswesen sind die im Gesundheitswesen oder in der Gesundheitsweisen Hangel treiben, Behörden und anderen öffentlich-rechtlichen Institutionen sowie die Einrichtungen der gemeinsamen Selbstverwaltung im Gesundheitswesen. Hierzu zählen auch die europäischen Behörden (z.B. die EU-Kommission und die EMA) (FSA Kodeu). Kodeu).

2 Medizin, Market Access in einer nicht-kommerziellen Funktion, HEOR, GDD- entsprechende Funktion eintragen

Nutzungshinweis unsolicited request

- 1. Dieses Material wird Ihnen zur Beantwortung Ihrer Anfrage zur Verfügung gestellt. Es enthält möglicherweise Informationen zu Produkten oder Indikationen, die derzeit erforscht werden und noch keine Zulassung besitzen.
- 2. Dieses Material dient rein wissenschaftlichen Informationszwecken und ist nicht zur werblichen Verwendung vorgesehen.
- 3. Die Inhalte dieses Materials entsprechen zum Zeitpunkt ihrer Entstehung unserem besten Wissensstand. Alle Angaben zu Wettbewerbern gründen sich auf öffentlich zugängliche Quellen. Richtigkeit und Zusammenhang zum Zeitpunkt der Nutzung unterliegen der Verantwortung des Nutzers.
- 4. Änderungen, die am Inhalt dieses Materials vorgenommen werden, liegen nicht in der Verantwortung von Novartis. Richtigkeit und Zusammenhang bei einer Verwendung zu einem späteren Zeitpunkt unterliegen der Verantwortung jener Person, die das Material verwendet.
- 5. Stand 12/2020

PD2-06

Clinical Outcomes of Alpelisib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer With *PIK3CA* Alterations Detected in Plasma ctDNA by Next-Generation Sequencing: Biomarker Analysis From the SOLAR-1 Study

Eva M. Ciruelos,¹ Sibylle Loibl,² Ingrid A. Mayer,³ Mario Campone,⁴ Hope S. Rugo,⁵ Monica Arnedos,⁶ Hiroji Iwata,⁷ Pierfranco Conte,⁸ Fabrice André,⁶ Albert Reising,⁹ Chong Ma,¹⁰ Michelle Miller,⁹ Naveen Babbar,¹⁰ Dejan Juric¹¹

¹University Hospital 12 de Octubre, Madrid, Spain; ²German Breast Group, Neu-Isenburg, Germany; ³Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN; ⁴Institut de Cancérologie de l'Ouest, St. Herblain, France; ⁵University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ⁶Institut Gustave Roussy, Villejuif, France; ⁷Aichi Cancer Center Hospital, Aichi, Japan; ⁸Istituto Oncologico Veneto, University of Padua, Padua, Italy; ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ; ¹⁰Novartis Pharmaceuticals Corporation, Cambridge, MA; ¹¹Department of Oncology/Hematology, Gillette Center for Women's Cancer, Massachusetts General Hospital Cancer Center, Boston, MA

San Antonio Breast Cancer Symposium Virtual Symposium 2020 December 8-11, 2020


Disclaimer

- This material was reviewed by the Global Medical Review team and is recommended for external presentation in response to an unsolicited medical request subject to local approval
- This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities
- Each CPO is responsible for ensuring that this material is used in accordance with local laws, regulations, industry, and Novartis codes and standards

Background (1 of 3)

- Approximately 40% of cases of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) contain mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*) gene.¹⁻⁶
 - The majority of mutations occur in exons 9 and 20 of *PIK3CA* and are found to a lesser extent in exon 7.⁷⁻⁸
- SOLAR-1 is the first Phase III trial investigating specific inhibition of the effects of *PIK3CA* with alpelisib in combination with fulvestrant in HR+, HER2– ABC post endocrine therapy (Figure 1).
 - SOLAR-1 demonstrated clinical benefit in patients with HR+, HER2–, *PIK3CA*-mutated ABC in the post-endocrine therapy setting.⁹⁻¹²

Background (2 of 3) Figure 1. Study Design



Primary endpoint

• PFS in *PIK3CA*-mutant cohort (locally assessed)

Key secondary endpoint

OS (PIK3CA-mutant cohort)

Secondary endpoints include

- PFS in patients with PIK3CA mutation in ctDNA
- · ORR/CBR
- Safety
- · Global health status/quality of life

^a Fulvestrant given on Day 1 and Day 15 of the first 28-day cycle, then Day 1 of subsequent 28-day cycles.

ABC, advanced breast cancer; AI, aromatase inhibitor; CBR, clinical benefit rate; CDK4/6, cyclin-dependent kinases 4 and 6; ctDNA, circulating tumor DNA; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2–, human epidermal growth factor receptor 2–negative; HR+, hormone receptor–positive; IM, intramuscular; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PO, orally; QD, daily; R, randomization.

Background (3 of 3)

- In SOLAR-1, prospective *PIK3CA* mutation testing was performed on tumor tissue in a central laboratory using polymerase chain reaction (PCR)-based assays and patients were assigned to a cohort on the basis of this test.
 - The initial screening assay could detect 11 specific mutations in exons 7, 9, and 20.
 - In the cohort of patients with *PIK3CA* mutations, median progression-free survival (mPFS) was 11.0 months and 5.7 months in patients receiving alpelisib + fulvestrant vs placebo + fulvestrant, respectively (primary endpoint of SOLAR-1, hazard ratio [HR] 0.65; 95% confidence interval [CI], 0.50-0.85; 1-sided *P*=0.00065).⁹⁻¹¹
 - In a secondary endpoint analysis, mPFS was 10.9 months and 3.7 months in patients with a *PIK3CA* mutation (as assessed retrospectively by PCR on plasma circulating tumor DNA [ctDNA] collected at baseline and analyzed retrospectively) receiving alpelisib + fulvestrant vs placebo + fulvestrant, respectively (HR 0.55; 95% CI, 0.39-0.79).¹⁰
- Retrospective analyses by next-generation sequencing (NGS) identified *PIK3CA* alterations in tumor tissue, and efficacy of alpelisib was demonstrated in patients whose tumors harbor *PIK3CA* alteration(s) as detected by NGS.^{13,14}

PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Objective

• The objective of this exploratory biomarker analysis was to assess clinical outcomes of patients with *PIK3CA* alteration(s) as detected in plasma ctDNA through retrospective analysis by an NGS assay.

ctDNA, circulating tumor DNA; NGS, next-generation sequencing; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Methods

Biomarker Analyses

- Retrospectively, the full exonic region of the *PIK3CA* gene was sequenced using the Foundation Medicine panels in tumor tissue (FoundationOne[®] CDx 324-gene panel) and plasma ctDNA (FoundationOne[®] Liquid CDx 311-gene panel) collected at baseline.
 - Using NGS testing, the exploratory analysis was performed for all patients with sufficient samples (quantity/quality) independently of their tumor tissue alteration status as detected by PCR.
 - The NGS test detected additional *PIK3CA* alterations that were not detectable by the PCR assays used during SOLAR-1 screening.
 - The prospective screening assay was performed on formalin-fixed, paraffin-embedded (FFPE) tumor specimens using a validated Novartis clinical trial assay and/or the QIAGEN *therascreen*® *PIK3CA* RGQ PCR Kit. Per this prospective screening, patients with specific mutations in exons 7, 9, and 20 (C420R, E542K, E545A/D/G/K, Q546E/R, H1047L/R/Y) were enrolled in SOLAR-1.
 - For NGS testing, a *PIK3CA* alteration is defined as single or multiple genetic changes (leading or not leading to amino acid changes) or a copy number variation (amplification).
- PFS was assessed using Kaplan–Meier methodology per investigator assessment. ctDNA, circulating tumor DNA; NGS, next-generation sequencing; PCR, polymerase chain reaction; PFS, progression free-survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
- 9 2020 SABCS Biomarker Analysis SOLAR-1 Study | Dec 2020 | For presentation in response to an unsolicited request for medical information subject to local approval

Results (1 of 16) NGS Analysis

- Of 572 patients in SOLAR-1, 381 patients (67%) across both *PIK3CA*-mutant and non-mutant cohorts had valid plasma ctDNA data.
- Of these patients, 193 (51%) had a *PIK3CA* alteration (genetic or amino acid change or copy number variation) in ctDNA (Table 1).

ctDNA, circulating tumor DNA; NGS, next-generation sequencing; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (2 of 16)

Table 1. Available Samples of Plasma ctDNA at Baseline

	Patients With a <i>PIK3CA</i> Alteration per NGS (n=193)
Number of alterations, n (%)	
Single alteration	147 (76)
Multiple alterations	46 (24)
Detectable by PCR, n (%)	
Yes	168 (87)
No	25 (13)
Exon 7 alteration, n (%)ª	11 (6)
Exon 9 alteration, n (%)	70 (36)
Exon 20 alteration, n (%)	102 (53)

^a No further analysis was performed on patients with alterations in exon 7 due to the low number.

ctDNA, circulating tumor DNA; NGS, next-generation sequencing; PCR, polymerase chain reaction; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (3 of 16)


mPFS in Patients by *PIK3CA* Alteration Status in Plasma ctDNA as Detected by NGS

- In the *PIK3CA*-altered group, treatment with alpelisib + fulvestrant resulted in improved PFS compared with placebo (mPFS: 11.0 mo vs 3.7 mo; HR 0.47; 95% CI, 0.33-0.67; **Figure 2**).
- In the *PIK3CA*-non-altered group, treatment with alpelisib + fulvestrant indicated improved PFS compared with placebo (mPFS: 10.9 mo vs 5.5 mo; HR 0.60; 95% CI, 0.40-0.91; **Figure 2**).

ctDNA, circulating tumor DNA; HR, hazard ratio; mo, months; mPFS, median progression-free survival; NGS, next-generation sequencing; PFS, progression-free survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; vs, versus.

Results (4 of 16)

Figure 2. Kaplan–Meier mPFS in Patients by PIK3CA Alteration Statusa in Plasma ctDNA as Detected by NGS



Group ^a	Events	N	mPFS (95% Cl)	HR (95% CI)	
Placebo + fulvestrant/ PIK3CA non-altered	60		5.5 (3.8-9.0)	0.60	
Alpelisib + fulvestrant/ PIK3CA non-altered	40	87	10.9 (5.6-16.8)	(0.40-0.91)	
Placebo + fulvestrant/ <i>PlK3CA</i> altered	73	92	3.7 (2.9-6.8)	0.47	
Alpelisib + fulvestrant/ <i>PIK3CA</i> altered	58	101	11.0 (7.7-16.2)	(0.33-0.67)	

^aAlteration status as detected in plasma ctDNA by NGS.

CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mPFS, median progression-free survival; NGS, next-generation sequencing; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (5 of 16)

Deeper Understanding of Alpelisib Efficacy in Patients With *PIK3CA* Non-altered Status in Plasma ctDNA

• Of the patients in the ctDNA non-altered subgroup, 38% (72/188) had *PIK3CA* alteration(s) in tissue as detected by NGS, PCR, or both (**Table 2**).

Table 2. Tissue Alterations by NGS and PCR in the Plasma ctDNANon-altered Population

(n=188)						
Tissue	Altered	Non-altered	NA			
NGS, n	39	98	51			
PCR, n	67	121	0			

ctDNA PIK3CA Non-altered Population

ctDNA, circulating tumor DNA; NA, not availablel; NGS, next-generation sequencing; PCR, polymerase chain reaction; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha


Results (6 of 16)

- For patients treated with alpelisib plus fulvestrant, those in the ctDNA non-altered subgroup with tissue alterations in *PIK3CA*, as detected by NGS, had longer mPFS (22.1mo [n=20]) than those with non-altered tissue *PIK3CA* (9.2 mo [n=43]; Figure 3).
 - These results should be interpreted with caution due to the low number of patients in each subgroup.
- This result suggests that when no *PIK3CA* alteration is detected in plasma ctDNA, alteration(s) in tumor tissue should be investigated to confirm the *PIK3CA* status of the tumor.

ctDNA, circulating tumor DNA; mo, months; mPFS, median progression-free survival; NGS, next-generation sequencing; PCR, polymerase chain reaction; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

Results (7 of 16)

Figure 3. Kaplan–Meier mPFS in Patients Without *PIK3CA* Alteration(s) in ctDNA as Detected by NGS by Tissue Alteration Status^a



Group	Events	N	mPFS (95% Cl)	HR (95% CI)	
Placebo + fulvestrant/ <i>PIK3CA</i> non-altered	31	55	5.1 (3.7-9.0)	0.69 (0.38-1.27)	
Alpelisib + fulvestrant/ PIK3CA non-altered	18	43	9.2 (3.8-NA)		
Placebo + fulvestrant/ PIK3CA altered	11	19	10.1 (3.6-NA)	0.54	
Alpelisib + fulvestrant/ <i>PIK3CA</i> altered	8	20	22.1 (5.5-NA)	(0.19-1.50)	

^aAlteration status as detected in plasma ctDNA by NGS.

CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mPFS, median progression-free survival; NGS, next-generation sequencing; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (8 of 16)


PIK3CA Alteration(s) in Tumor Tissue vs Plasma ctDNA: Investigating the Discordance

- ctDNA allele frequency
 - Patients who did not have a *PIK3CA* alteration detected in ctDNA but were found to have a *PIK3CA* alteration in tissue had lower maximum allele frequency in ctDNA (Figure 4).
 - Maximum allele frequency was determined, in ctDNA, using all somatic alterations, or those with an allele frequency below 40% (indicating a possible germline alteration).
 - This indicates that ctDNA may not be identifying patients with low tumor allele frequencies due to ctDNA test sensitivity.

ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (9 of 16)

Figure 4. ctDNA Maximum Allele Frequency for Patients With *PIK3CA* Alteration or Non-alteration in Tissue by Plasma ctDNA Alteration Status



Cl, confidence interval; ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (10 of 16)


Tissue Allele Frequency

- In patients who were found to have a *PIK3CA* alteration in tissue but not in plasma ctDNA, tissue *PIK3CA* allele frequency was lower than that of ctDNA *PIK3CA*-altered patients (Figure 5).
 - This lower allele frequency may indicate differences in tumor DNA shedding.

ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (11 of 16)

Figure 5. Tissue *PIK3CA* Allele Frequency for Patients With *PIK3CA* Alteration in Tissue by Plasma ctDNA Alteration Status



CI, confidence interval; ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.


Results (12 of 16) Blood Tumor Mutation Burden

- Patients who did not have a *PIK3CA* alteration detected in ctDNA but were found to have a *PIK3CA* alteration in tissue had lower blood tumor mutation burden (Figure 6).
 - This observation, along with differences in maximum allele frequency, may further indicate a difference in tumor DNA shedding leading to a non-altered finding in ctDNA.

ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (13 of 16)

Figure 6. Blood Tumor Mutation Burden for Patients With *PIK3CA* Alteration or Non-alteration in Tissue by Plasma ctDNA Alteration Status



Cl, confidence interval; ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Results (14 of 16)

mPFS in Patients With *PIK3CA* Alteration(s) in ctDNA as Detected by NGS in Subgroups of Interest

- In patients with PCR-detectable alterations, a benefit of alpelisib + fulvestrant vs placebo + fulvestrant was observed (mPFS: 12.5 mo vs 3.6 mo; HR 0.44; 95% CI, 0.30-0.64; Figure 7).
- In the small group of alpelisib-treated patients with alterations not detectable by PCR, (n =13), no benefit from treatment with alpelisib + fulvestrant vs placebo + fulvestrant was observed (mPFS: 8.5 mo vs 7.4 mo; HR 1.12; 95% CI, 0.35-3.56; Figure 7).
- Patients with single (n=147) or multiple (n=46) *PIK3CA* alterations benefited similarly from treatment with alpelisib + fulvestrant vs placebo + fulvestrant (PFS HR for patients with single alterations: 0.43 [95% CI, 0.28-0.65]; PFS HR for patients with multiple alterations: 0.55 [95% CI, 0.25-1.20]; Figure 7).
 - Patients with multiple PIK3CA alterations had shorter mPFS with alpelisib (9.0 mo) than those with single alterations (12.9 mo); however, results should be interpreted with caution due to the small number of patients (n=46 with multiple alterations).

CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mo, months; mPFS, mean progression free-survival; PCR, polymerase Chain Reaction; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; vs, versus.

Results (15 of 16)

- Similar benefit was seen in patients with alterations in either exon 9 or exon 20 (PFS HR for patients with exon 9 alteration: 0.31 [95% CI, 0.16-0.61]; PFS HR for patients with exon 20 alteration: 0.51 [95% CI, 0.31-0.82]; Figure 7).
- Results should be interpreted with caution due to the small number of patients in some subgroups.

CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mo, months; PFS, progression-free survival;

Results (16 of 16)

Figure 7. mPFS in Patients With *PIK3CA* Alteration(s) in ctDNA as Detected by NGS in Subgroups of Interest

	Alpelisib + Fulvestrant		Placebo + Fulvestrant					
	Events/N	mPFS, mo (95% Cl)	Events/N	mPFS, mo (95% Cl)				HR (95% Cl)
MK3CA: Alteration s	tatus as detect	ed by NGS						
Altered	58/101	11.0 (7.7-16.2)	73/92	3.7 (2.9-6.8)	+	1		0.47 (0.33-0.67)
Non-altered	40/87	10.9 (5.6-16.8)	60/101	5.5 (3.8-9.0)				0.60 (0.40-0.91)
NK3CA: Alteration s	tatus as detect	ed by PCR ^a						
Detectable	52/88	12.5 (7.4-18.4)	66/80	3.6 (2.4-5.7)	-	1		0.44 (0.30-0.64)
Not detectable	6/13	8.5 (2.7-NA)	7/12	7.4 (1.9-13.0)		•		1.12 (0.35-3.56)
K3CA: Number of a	alterations							
Single	45/83	12.9 (7.4-18.5)	50/64	3.6 (1.9-6.1)	-			0.43 (0.28-0.65)
Multiple	13/18	9.0 (3.7-18.4)	23/28	4.6 (3.5-9.6)				0.55 (0.25-1.20)
K3CA: Alterations	in exon 9 or exc	on 20						
Exon 9	18/34	15.2 (7.0-NA)	29/36	3.7 (2.9-7.4)				0.31 (0.16-0.61)
Exon 20	34/54	10.9 (5.7-18.4)	40/48	3.5 (1.9-6.1)				0.51 (0.31-0.82)
					0	1 2	3	4
				Fav	ors alpelisib	Favors placeb	0	

^aAlteration detectable by PCR refers to the mutations as detected by the validated Novartis clinical trial assay and/or the QIAGEN *therascreen*® PIK3CA RGQ PCR Kit. CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; mo, months; mPFS, median progression-free survival; NA, not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Conclusions (1 of 2)

- The data presented here indicated the clinical benefit of alpelisib + fulvestrant in patients with HR+, HER2– ABC with *PIK3CA* alterations in either plasma ctDNA or tissue FFPE as detected by NGS.
- The clinical benefit of alpelisib observed in this study is consistent with that observed in patients with *PIK3CA* alteration(s) in tumor tissue as detected by NGS and PCR
 - In subgroups of interest (including patients with PCR-detectable alterations, multiple/single alterations, and exon 9/20 alterations), a consistent PFS benefit was observed.
 - Limited benefit was observed for alpelisib + fulvestrant in the subgroup of patients with PIK3CA alterations not detectable by PCR.
 - Caution should be taken in interpreting these results due to the small number of patients in some subgroups.

ABC, advanced breast cancer; ctDNA, circulating tumor DNA; FFPE, formalin-fixed paraffin-embedded; HR+, hormone receptor-positive; HER2–, human epidermal growth factor receptor 2–negative; NGS, next-generation sequencing; PCR, polymerase chain reaction; *PIK3CA*, phosphatidylinositol-4,5 bisphosphate 3-kinase catalytic subunit alpha.

Conclusions (2 of 2)

- Additional analysis indicated that *PIK3CA* alteration in tissue is driving the clinical benefit observed in non-altered plasma ctDNA patients, which supports the reflex testing paradigm.
 - When no *PIK3CA* alteration is detected by ctDNA liquid biopsy, a tissue test should be performed to confirm the *PIK3CA* status of the tumor.
- Discordance between the tissue and plasma *PIK3CA* alteration results was due to both technical (test performance) and biological (ctDNA shedding) aspects.
 - Low allele frequency of mutations in tumor tissue at primary tumor or metastatic sites may lead to low representation of alterations in ctDNA, which could be lower than the detection limit of the assay.
 - Variable DNA shedding rates between tumors may also limit *PIK3CA* alteration(s) detection by ctDNA.

ctDNA, circulating tumor DNA; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

References

- 1. Cancer Genome Atlas Network. *Nature*. 2012;490(7418):61-70.
- 2. Di Leo A, et al. Lancet Oncol. 2018;19(1):87-100.
- 3. Mollon L, et al. AACR 2018. Poster 1207.
- 4. Moynahan ME, et al. Br J Cancer. 2017;116(6):726-730.
- 5. Tolaney S, et al. AACR 2019. Abstract 4458 (oral presentation).
- 6. Baselga J, et al. Lancet Oncol. 2017;18(7):904-916.
- 7. Ligresti G, et al. Cell Cycle. 2009;8(9):1352-1358.
- 8. Samuels Y, et al. *Science*. 2004;304(5670):554.
- 9. André F, et al. ESMO 2018. Abstract LBA3 (oral presentation).
- 10. Juric D, et al. SABCS 2018. Abstract GS3-08 (oral presentation).
- 11. André F, et al. N Engl J Med. 2019;380(20):1929-1940.
- 12. André F, et al. ESMO 2020. LBA 18 (oral presentation).
- 13. Juric D, et al. SABCS 2019. Poster P4-10-04.
- 14. Rugo HS, et al. AACR 2019. Abstract CT142 (poster).

^{28 2020} SABCS Biomarker Analysis SOLAR-1 Study | Dec 2020 | For presentation in response to an unsolicited request for medical information subject to local approval

Acknowledgements

This study was sponsored by Novartis Pharmaceuticals Corporation.

Medical editorial assistance was provided by Peggy Robinet, PharmD, PhD, of Healthcare Consultancy Group, LLC, and funded by Novartis Pharmaceuticals Corporation.

Disclosures

Eva M. Ciruelos: Honoraria, consulting fees, and speaker fees from Novartis, Eli Lilly, Roche, and Pfizer; consulting fees from AstraZeneca; and travel and accommodations paid by Roche and Pfizer. Sibyle Loibl: Grants and honoraria from AstraZeneca during the conduct of the study; grants and honoraria from AbbVie, Amgen, BMS, Eirgenix, Celgene, Daiichi-Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Puma, Roche, and Samsung; honoraria from Seattle Genetics, and PriME/Medscape; personal fees from Chugai; grants from Immunomedics, Teva, and Vifor outside the submitted work; and patent EP14153692.0 pending. Ingrid A. Mayer: Payment for consulting from Novartis, Genentech, Eli Lilly, AstraZeneca, GSK, Immunomedics, MacroGenics, Seattle Genetics, AbbVie, and Puma; and grants from Novartis, Genentech, and Pfizer. Mario Campone: Grants and nonfinancial support from Novartis during the conduct of the study; grants from Roche and TESSARO; personal fees from Roche, AstraZeneca, and Pfizer; and advisory board fees from Servier, Sanofi, and Accord outside the submitted work. Hope S. Rugo: Research funding from Pfizer, Merck, Novartis, Eli Lilly, Genentech, OBI, Odonate, Daiichi-Sankyo, Eisai, Seattle Genetics, MacroGenics, and Immunomedics; consulting fees from Samsung; advisory boards for Puma and Celtrion; and travel and accommodations paid by Daiichi-Sankyo, Mylan, Pfizer, Merck, AstraZeneca, and Macrogenics. Monica Arnedos: Investigator fees from Novartis during the conduct of the study; personal fees from Seattle Genetics, Pfizer, Novartis, and AstraZeneca; and investigator fees from Puma outside the submitted work. Hiroji lwata: Honoraria and consulting fees from Daiichi-Sankyo, Chugai, AstraZeneca, Pfizer, Eli Lilly, and Novartis; honoraria from Taiho and Eisai; and consulting fees from Kyowa Kirin, AbbVie, and Odonate. Pierfranco Conte: Speaker fees from Roche/Genentech, Novartis, and AstraZeneca; research funding from Roche, Novartis, and Merck Serono; and travel and accommodations paid by Novartis, Celgene, and AstraZeneca. Fabrice André: Grants from Novartis during the conduct of the study; and grants from AstraZeneca, Pfizer, Eli Lilly, Roche, and Daiichi-Sankyo outside the submitted work. Albert Reising: Employee of Novartis Pharmaceuticals Corporation and holds Novartis stock options. Chong Ma: Employee of Novartis Pharmaceuticals Corporation and holds Novartis stock options. Michelle Miller: Employee of Novartis Pharmaceuticals Corporation and holds Novartis stock options. Naveen Babbar: Employee of Novartis Pharmaceuticals Corporation and holds Novartis stock options. Dejan Juric: Grants and personal fees from Novartis during the conduct of the study; grants and personal fees from Genentech, Eisai, EMD Serono, Petra Pharma, and Syros; personal fees from Ipsen, Relay Therapeutics, MapKure, and Vibliome; and grants from Takeda, Amgen, Celgene, Placon Therapeutics, InventisBio, and Infinity Pharmaceuticals outside the submitted work.

Presented at the San Antonio Breast Cancer Symposium Virtual Symposium 2020; December 8-11 2020. Poster PD2-06.

This study was sponsored by Novartis Pharmaceuticals Corporation.

This presentation is the intellectual property of the author/presenter. Contact Eva M. Ciruelos at eva.ciruelos@gmail.com for permission to reprint and/or distribute.

For a poster reprint or a plain-language summary: Text: Q760dd

To: 8NOVA (86682) US Only +18324604729 North, Central and South Americas; Caribbean; China +447860024038 UK, Europe & Russia +46737494608 Sweden, Europe

View this poster on the web at:

http://novartis.medicalcongressposters.com/Default.aspx?doc=760dd

Scan this QR code



Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission from authors.

This presentation is the intellectual property of the author/presenter.

Contact them at eva.ciruelos@gmail.com for permission to reprint and/or distribute.